Immunogenicity and Safety of Vaccination Against Tick Borne Encephalitis (TBE) in Patients Living With Multiple Sclerosis (MS) (MS and TBE vac)
This is a monocenter, prospective cohort study. The study investigates the response of patients living with multiple sclerosis (MS) to vaccination against tick-borne viral encephalitis (TBE).
The prevalence of TBE has increased significantly in Switzerland over the past two decades. Whereas previously only the lowland regions of northern Switzerland and the Aare Valley were considered areas where TBE vaccination was indicated, the disease is now endemic throughout Switzerland (except for Ticino). Since TBE specifically affects the nervous system, there is a clear indication for vaccination, particularly for people whose nervous system is already compromised.
MS is the most common neurological autoimmune disease among young adults in northern latitudes. It is a progressive disease characterized by a gradual deterioration of neurological functions. The course of the disease can be slowed through immunomodulatory therapies. However, these therapies also lead to a certain degree of immunosuppression, which may reduce the immune response to vaccinations. At the same time, some people with MS experience fear or scepticism towards vaccinations, as infections often lead to a worsening of symptoms or can trigger a relapse. Since vaccinations mimic an infection to some extent, this concern is sometimes transferred to vaccinations as well.
The study hypothesizes that the TBE vaccine in people living with MS on non-B-cell depleting treatment shows adequate immunogenicity.
Moreover, the study will assess the safety of TBE vaccination.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Cornelia Staehelin, PD. Dr. med.
- Número de teléfono: +41 31 632 01 83
- Correo electrónico: cornelia.staehelin@insel.ch
Copia de seguridad de contactos de estudio
- Nombre: Robert Hoepner, Prof. Dr. med.
- Número de teléfono: +41 316325835
- Correo electrónico: robert.hoepner@insel.ch
Ubicaciones de estudio
-
-
-
Bern, Suiza, 3010
- Reclutamiento
- University Hospital of Bern
-
Contacto:
- Cornelia Staehelin, PD Dr. med
- Número de teléfono: +41 31 632 01 83
- Correo electrónico: cornelia.staehelin@insel.ch
-
Contacto:
- Robert Hoepner, PD Dr. med.
- Número de teléfono: +41 +41 632 60 93
- Correo electrónico: robert.hoepner@insel.ch
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The investigators target a sample size of 50 people living with MS with stable RRMS (no evidence of disease activity -NEDA-3 status - as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI) for ≥ 1 year prior to inclusion into the study and treated with non-B-cell depleting therapies for at least 6 months in monotherapy.
In order to have a homogenous and stable patient population, the investigators decided to include only patients without evidence of disease activity for at least 1 year prior to inclusion. Considering the latter the investigators classify any disease reactivation during the period of 42 days (+/- 7days) after the first dose / booster dose as related to the intervention (vaccination).
Descripción
Inclusion Criteria
-
Adult (≥ 18 years old)
-
Suspected neuroimmunological disorder with CNS affection
- including suspicion of Multiple Sclerosis (MS)
- Diagnosed Multiple Sclerosis (MS)
- Clinically Isolated Syndrome
- Radiologically Isolated Syndrome
-
stable RRMS - defined as no evidence of disease activity-NEDA-3 status-as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI for ≥ 1 year prior to inclusion
-
treated with non-B-cell depleting therapies for at least 6 months in monotherapy
-
TBE vaccine:
- never been vaccinated against TBE or
- clinical indication for booster vaccination (person living with MS and has had primary series of 3 vaccines of which the last one was ≥ 10 years ago)
-
Provided written informed consent
Exclusion Criteria
- Any B-cell depleting therapies in last 12 months prior to recruitment
- Any other vaccination in last 2 months prior to recruitment
- Any foreseeable and necessary other vaccination up to 42 days post dose 1
- Immunoglobulin-Infusion (intravenous or subcutaneous, IVIG or SCIG) in the last 4 months prior to the drawing of study samples
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
|---|
|
Primary vaccination series or Booser against TBE in patients with MS
According to Swiss guidelines, patients with MS will receive the primary vaccination series (3 doses) against TBE (if they have never been vaccinated) or a TBE booster (if they have already received the primary vaccination series and their last vaccination was ≥ 10 years ago). |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Primary immunogenicity endpoint
Periodo de tiempo: 42 days post dose 1
|
Change in antibody concentration (GMC) from baseline to day 42 post dose 1 as measured by ELISA |
42 days post dose 1
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Immunogenicity endpoint
Periodo de tiempo: 42 days post dose 1
|
Change in antibody titers as measured by serum neutralizing test (SNT) from baseline to day 42 (post dose 1) |
42 days post dose 1
|
|
Immunogenicity endpoint
Periodo de tiempo: 7 months post dose 1 or 6 months post booster dose
|
Change in antibody titers as measured by ELISA from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose. |
7 months post dose 1 or 6 months post booster dose
|
|
Immunogenicity endpoint
Periodo de tiempo: 7 months post dose 1 or 6 months post booster dose
|
Change in antibody titers as measured by SNT from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose. |
7 months post dose 1 or 6 months post booster dose
|
|
Immunogenicity endpoint
Periodo de tiempo: at each time point (7 months)
|
Seropositivity as measured by ELISA . Seropositivity is defined as IgG antibody concentration >150 U/ml for ELISA. |
at each time point (7 months)
|
|
Immunogenicity endpoint
Periodo de tiempo: at each time point (7 months)
|
Seropositivity as measured by SNT at each time point. Seropositivity is defined as antibody titer >1:10 for SNT. |
at each time point (7 months)
|
|
Safety endpoint
Periodo de tiempo: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Incidence of MS-relapses - defined clinically, according to clinical expert judgement, by the presence of MS-typical symptoms with objectifiable findings lasting more than 24 hours, without fever or infection. |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Periodo de tiempo: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Activity in cerebral MRI scan (new or enlarging lesions or gadolinium uptake) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Periodo de tiempo: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Neurological assessment (EDSS) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Periodo de tiempo: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Multivariable blood biomarker based scores for MS disease activity (MSDA) and disease pathways (Octave Bioscience, USA) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Periodo de tiempo: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Vaccine reactogenicity (solicited and unsolicited local and systemic vaccine reactions) |
42 (+/-7d) post dose 1
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Encefalitis infecciosa
- Enfermedades transmitidas por vectores
- Enfermedades Neuroinflamatorias
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Infecciones
- Infecciones por virus de ARN
- Enfermedades virales
- Enfermedades Autoinmunes Desmielinizantes, SNC
- Enfermedades Autoinmunes del Sistema Nervioso
- Enfermedades desmielinizantes
- Infecciones por arbovirus
- Infecciones por Flavivirus
- Infecciones por Flaviviridae
- Enfermedades transmitidas por garrapatas
- Encefalitis Viral
- Enfermedades Virales del Sistema Nervioso Central
- Infecciones del Sistema Nervioso Central
- Encefalitis
- Encefalitis, Arbovirus
- Esclerosis múltiple
- Encefalitis Transmitida Por Garrapatas
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2025-01767
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .